Prescription Medicines
Aclova Inj.
- Product Category
- antiviral drugs
- Active Ingredients
- acyclovir
- Appearance
- White to milky white powder or cake-like lump in a colorless and transparent vial
- Reimbursement Code
- 648101541
01 / 02
1. Composition and Strength
- Active ingredient: Acyclovir (USP)--------- 250mg
- Additives: Sodium hydroxide, distilled water for injection
2. Effectiveness
1. Patients with normal immune function: Severe primary genital herpes, recurrent varicella-zoster virus infection, herpes simplex encephalitis
2. Patients with compromised immune function: Treatment and prevention of herpes simplex virus infection, primary and recurrent varicella-zoster virus infection, herpes simplex encephalitis
3. Dosage and dosage
Injectable drugs are administered intravenously slowly over 1 hour for each administration. The appropriate administration period is 5 days, but can be adjusted depending on the patient's symptoms and healing status. Herpes simplex encephalitis is usually administered for 10 days.
1. Adult
1) Herpes simplex infection: Patients with normal or decreased immune function are administered acyclovir at 5 mg per kg of body weight every 8 hours.
2) Recurrent varicella-zoster virus infection: Patients with normal immune function should be administered 5 mg per kg of body weight every 8 hours.
3) Primary and recurrent varicella-zoster virus infection: Patients with weakened immune function should be administered 10 mg/kg of body weight every 8 hours.
4) Herpes simplex encephalitis: Patients with normal or decreased immune function should be administered 10 mg per kg of body weight every 8 hours.
5) Prevention of herpes simplex virus infection in patients with weakened immune function: Considered in cases where oral administration is not possible, and the administration period is determined according to the infection risk period.
6) Obese patients: When obese patients inject acyclovir intravenously according to their actual body weight, the plasma concentration may increase. Therefore, dose reduction should be considered in obese patients, especially those with renal impairment or elderly patients.
2. Patients with renal impairment are prone to mental and nervous system adverse reactions, so caution is required when administering the drug. The dosage is as follows.
- Creatinine clearance rate (mL/min): 25~50
Administer the recommended dose for each indication above every 12 hours.
- Creatinine clearance rate (mL/min): 10~25
Administer the recommended dose for each indication above every 24 hours.
- Creatinine clearance (mL/min): 0 (anuria) ~ 10
Patients receiving peritoneal dialysis should take half the recommended dose (2.5 or 5 mg per kg of body weight) every 24 hours. For patients receiving hemodialysis, half the recommended dose (2.5 or 5 mg per kg of body weight) is administered every 24 hours and after dialysis.
3. Pediatrics
Children (3 months to 12 years) Dosage is calculated according to body surface area and administered in accordance with adults.
1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours.
2) Immunocompromised children infected with varicella-zoster or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. For pediatric patients with renal impairment, the dosage should be adjusted appropriately depending on the degree of impairment.
4. Solution preparation
1 Add 10 mL of water for injection or intravenous saline solution (0.9%w/v) to a vial (containing 250 mg of acyclovir) and dissolve it, then inject intravenously using an infusion pump that can control the injection amount, or dilute and inject intravenously by drop.
5. Method of administration
1) When injecting intravenously using an IV pump, inject 25 mg/mL of acyclovir as is over 1 hour.
2) When diluted and administered intravenously by drip, the concentration of acyclovir must be less than 0.5%w/v, and a vial containing 250 mg must be diluted with a solution of 50 mL or more and injected over 1 hour.
3) In this case, the following drop solution can be used when diluted, and it is stable for 12 hours at room temperature (15-25℃).
(1) 0.45%w/v or 0.9%w/v physiological saline injection solution for intravenous drip
(2) 0.18%w/v saline injection and 4%w/v glucose mixture for intravenous instillation
(3) 0.45%w/v saline injection and 2.5%w/v glucose mixture for intravenous instillation
(4) Compound sodium lactate solution for intravenous drip (Hartmann solution)
4) After adding this medicine to the drop solution, shake the mixture to mix completely.
5) If turbidity or crystals are seen in the solution before or during injection, discard the mixed solution and do not cool the solution.
4. Precautions for use
1. Do not administer to the following patients.
Patients with a history of hypersensitivity to this drug or its components or valacyclovir
2. Administer with caution to the following patients.
1) Patients with renal impairment (adverse mental and nervous system reactions are likely to occur)
2) Patients with liver failure (liver function is likely to worsen)
3) Infants, toddlers, children
4) Elderly people
3. Adverse reactions
1) Shock: In rare cases, anaphylactic shock or anaphylactoid reaction may occur, so observe thoroughly. If symptoms such as lowered blood pressure, difficulty breathing, or chest tightness appear, immediately stop administration and take appropriate measures.
2) Hypersensitivity reaction: Occasionally, rash, fever, blisters, urticaria-like erythema, urticaria, photosensitivity reaction with unknown frequency, and fixative drug rash may occur. If these symptoms appear, take appropriate measures, such as discontinuing administration.
3) Skin: Alopecia, erythema multiforme, cutaneous mucous membrane syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) may occur with unknown frequency.
4) Mental nervous system: Rarely, disturbance of consciousness, delirium, convulsions, anxiety, speech disorder, dizziness, occasional hallucinations, disorientation, confusion, numbness of the lower extremities, numbness of the tongue and limbs, tremors, lethargy, headache, general malaise, bipolar disorder, emotional instability, infrequent difficulty concentrating, depersonalization, forgetfulness, insomnia, ataxia, talking to oneself, abnormal sensations, gait abnormality, and involuntary movements may occur. Take appropriate measures, such as reducing the dose or discontinuing the dose.
5) Kidney: Acute renal failure, pyuria, crystalluria, sometimes BUN, elevated serum creatinine, rarely hematuria, proteinuria, urinary red blood cell casts, and very rarely acute renal failure may occur. If these symptoms appear, take appropriate measures such as reducing the dose or discontinuing the administration.
6) Liver: Hepatitis, liver failure, jaundice Occasionally abnormal liver function test values (elevated AST/ALT, LDH, ALP, γ-GTP, total bilirubin, etc.) may occur. In such cases, take appropriate measures, such as discontinuing administration.
7) Blood system: bleeding, increased leukocytes, increased basophils, decreased lymphocytes, increased platelets, agranulocytosis, sometimes anemia, rarely purpura, decreased platelets, decreased granulocytes, increased eosinophils, increased lymphocytes, and disseminated intravascular coagulation.
8) Digestive system: Gastritis, indigestion, glossitis, thirst, constipation, acute pancreatitis, sometimes nausea, vomiting, abdominal pain, stomach pain, epigastric pain, stomach discomfort, rarely diarrhea, loose stools, and loss of appetite may occur.
9) Circulatory system: Occasionally, chest pain, rarely palpitations, tachycardia, increased blood pressure, arrhythmia, and decreased blood pressure may occur with unknown frequency.
10) Musculoskeletal system: Joint pain and muscle pain may occur.
11) Urinary system: Difficulty urinating and urinary obstruction may occur.
12) Whole body: Edema, fainting, muscle weakness, sometimes general malaise, fever, headache, and in rare cases, pallor and coldness may appear.
13) Others: Pneumonia, laryngitis, pleural effusion, hearing loss, conjunctivitis, visual abnormalities, taste disorders, hair loss, sweating, hyponatremia, decreased serum albumin level, decreased serum potassium level, sometimes decreased protein content in the blood and increased cholesterol and triglyceride levels, difficulty in breathing, chest tightness, and rarely, urinary sugar may occur. Additionally, if the medication is accidentally injected into vascular tissue during administration, inflammation that causes ulcers may occur.
4. General precautions
1) This drug is most effective when administered as early in the disease as possible.
2) During administration of this drug (especially when administering high doses), sufficient fluid intake is necessary to prevent dehydration symptoms and reduce the risk of nephrotoxicity.
5. Interaction
1) It has been reported that the combined use of probenecid and this drug injection extends the average half-life of this drug by 18%, increases the area of the plasma-concentration curve by 40%, and reduces urinary excretion and renal clearance.
2) It has been reported that cimetidine reduces the urinary excretion of this drug and increases the area of the plasma-concentration curve by 27%.
3) It has been reported that the combined use of mycophenolate mofetil and this drug reduces the excretion of mycophenolate mofetil metabolites and increases the area of the plasma-concentration curve of both drugs.
4) When theophylline and this drug are used together, symptoms of theophylline poisoning may appear.
6. Administration to pregnant women
1) As a result of animal testing, teratogenic effects (abnormalities in the head and tail of the fetus) have been reported, so it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) Since the ingredients of this medicine are passed into breast milk, breast-feeding should be discontinued during treatment.
7. Administration to children
For infants, toddlers, and children, administer with caution, limiting use to the minimum necessary. In particular, safety for newborns and premature infants has not been established, so it is administered only when the therapeutic benefits are judged to outweigh the risks.
8. Administration to elderly people
This drug is mainly excreted through the kidneys. Elderly people often have reduced renal function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur. Therefore, administer with caution, paying attention to the dosage and administration interval.
9. Treatment in case of overdose
1) In cases where 20 g of this drug was taken at a time, agitation, lethargy, convulsions, and lethargy were reported as adverse reactions during overdose. In case of overdose, this drug may precipitate in the renal tubules, causing an increase in BUN and serum creatinine, and renal failure. In case of excessive intravenous administration, confusion, hallucinations, excitement, epileptic seizures, and coma may occur.
2) In case of overdose, the blood concentration of this drug should be measured while carefully observing the patient's condition. If symptoms of overdose appear, hemodialysis may be considered to lower the blood concentration of this drug.
10. Application precautions
1) Do not administer by rapid intravenous injection (bolus injection), but only by drip intravenous injection. To reduce risk to renal tubules, administer slowly by intravenous infusion over at least 1 hour.
2) During intravenous drip injection, vascular pain at the injection site and sudden weakening of blood vessels (easy to be exposed to extravasation) may occur at times, so administer carefully to prevent the drug from leaking outside the blood vessels.
3) Prepare the injection solution immediately before administration, shake sufficiently before administration, and discard the remaining solution after use. Additionally, when diluted with supplementary solution, cloudiness or crystals may precipitate due to the supplementary solution, so do not administer in such cases. Do not cool the preparation solution, including the diluted solution, because crystals are likely to precipitate when cooled.
4) This drug is alkaline and can easily change composition due to changes in pH, etc., so avoid mixing injections with other drugs if possible.
11. Others
1) In a bone marrow micronucleus test, it was reported that intraperitoneal administration of high doses (more than 180 mg/kg) to mice may cause chromosomal abnormalities.
2) Several recent studies have shown that this drug causes mutations and reduced spermatogenesis when administered in high doses. However, in human studies within the recommended dose range, there was no effect on sperm count.
4. How to save
Sealed container, stored below 25℃
5. Packaging unit
5 vials
6. Expiration date
60 months from date of manufacture
- Active ingredient: Acyclovir (USP)--------- 250mg
- Additives: Sodium hydroxide, distilled water for injection
2. Effectiveness
1. Patients with normal immune function: Severe primary genital herpes, recurrent varicella-zoster virus infection, herpes simplex encephalitis
2. Patients with compromised immune function: Treatment and prevention of herpes simplex virus infection, primary and recurrent varicella-zoster virus infection, herpes simplex encephalitis
3. Dosage and dosage
Injectable drugs are administered intravenously slowly over 1 hour for each administration. The appropriate administration period is 5 days, but can be adjusted depending on the patient's symptoms and healing status. Herpes simplex encephalitis is usually administered for 10 days.
1. Adult
1) Herpes simplex infection: Patients with normal or decreased immune function are administered acyclovir at 5 mg per kg of body weight every 8 hours.
2) Recurrent varicella-zoster virus infection: Patients with normal immune function should be administered 5 mg per kg of body weight every 8 hours.
3) Primary and recurrent varicella-zoster virus infection: Patients with weakened immune function should be administered 10 mg/kg of body weight every 8 hours.
4) Herpes simplex encephalitis: Patients with normal or decreased immune function should be administered 10 mg per kg of body weight every 8 hours.
5) Prevention of herpes simplex virus infection in patients with weakened immune function: Considered in cases where oral administration is not possible, and the administration period is determined according to the infection risk period.
6) Obese patients: When obese patients inject acyclovir intravenously according to their actual body weight, the plasma concentration may increase. Therefore, dose reduction should be considered in obese patients, especially those with renal impairment or elderly patients.
2. Patients with renal impairment are prone to mental and nervous system adverse reactions, so caution is required when administering the drug. The dosage is as follows.
- Creatinine clearance rate (mL/min): 25~50
Administer the recommended dose for each indication above every 12 hours.
- Creatinine clearance rate (mL/min): 10~25
Administer the recommended dose for each indication above every 24 hours.
- Creatinine clearance (mL/min): 0 (anuria) ~ 10
Patients receiving peritoneal dialysis should take half the recommended dose (2.5 or 5 mg per kg of body weight) every 24 hours. For patients receiving hemodialysis, half the recommended dose (2.5 or 5 mg per kg of body weight) is administered every 24 hours and after dialysis.
3. Pediatrics
Children (3 months to 12 years) Dosage is calculated according to body surface area and administered in accordance with adults.
1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours.
2) Immunocompromised children infected with varicella-zoster or herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. For pediatric patients with renal impairment, the dosage should be adjusted appropriately depending on the degree of impairment.
4. Solution preparation
1 Add 10 mL of water for injection or intravenous saline solution (0.9%w/v) to a vial (containing 250 mg of acyclovir) and dissolve it, then inject intravenously using an infusion pump that can control the injection amount, or dilute and inject intravenously by drop.
5. Method of administration
1) When injecting intravenously using an IV pump, inject 25 mg/mL of acyclovir as is over 1 hour.
2) When diluted and administered intravenously by drip, the concentration of acyclovir must be less than 0.5%w/v, and a vial containing 250 mg must be diluted with a solution of 50 mL or more and injected over 1 hour.
3) In this case, the following drop solution can be used when diluted, and it is stable for 12 hours at room temperature (15-25℃).
(1) 0.45%w/v or 0.9%w/v physiological saline injection solution for intravenous drip
(2) 0.18%w/v saline injection and 4%w/v glucose mixture for intravenous instillation
(3) 0.45%w/v saline injection and 2.5%w/v glucose mixture for intravenous instillation
(4) Compound sodium lactate solution for intravenous drip (Hartmann solution)
4) After adding this medicine to the drop solution, shake the mixture to mix completely.
5) If turbidity or crystals are seen in the solution before or during injection, discard the mixed solution and do not cool the solution.
4. Precautions for use
1. Do not administer to the following patients.
Patients with a history of hypersensitivity to this drug or its components or valacyclovir
2. Administer with caution to the following patients.
1) Patients with renal impairment (adverse mental and nervous system reactions are likely to occur)
2) Patients with liver failure (liver function is likely to worsen)
3) Infants, toddlers, children
4) Elderly people
3. Adverse reactions
1) Shock: In rare cases, anaphylactic shock or anaphylactoid reaction may occur, so observe thoroughly. If symptoms such as lowered blood pressure, difficulty breathing, or chest tightness appear, immediately stop administration and take appropriate measures.
2) Hypersensitivity reaction: Occasionally, rash, fever, blisters, urticaria-like erythema, urticaria, photosensitivity reaction with unknown frequency, and fixative drug rash may occur. If these symptoms appear, take appropriate measures, such as discontinuing administration.
3) Skin: Alopecia, erythema multiforme, cutaneous mucous membrane syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) may occur with unknown frequency.
4) Mental nervous system: Rarely, disturbance of consciousness, delirium, convulsions, anxiety, speech disorder, dizziness, occasional hallucinations, disorientation, confusion, numbness of the lower extremities, numbness of the tongue and limbs, tremors, lethargy, headache, general malaise, bipolar disorder, emotional instability, infrequent difficulty concentrating, depersonalization, forgetfulness, insomnia, ataxia, talking to oneself, abnormal sensations, gait abnormality, and involuntary movements may occur. Take appropriate measures, such as reducing the dose or discontinuing the dose.
5) Kidney: Acute renal failure, pyuria, crystalluria, sometimes BUN, elevated serum creatinine, rarely hematuria, proteinuria, urinary red blood cell casts, and very rarely acute renal failure may occur. If these symptoms appear, take appropriate measures such as reducing the dose or discontinuing the administration.
6) Liver: Hepatitis, liver failure, jaundice Occasionally abnormal liver function test values (elevated AST/ALT, LDH, ALP, γ-GTP, total bilirubin, etc.) may occur. In such cases, take appropriate measures, such as discontinuing administration.
7) Blood system: bleeding, increased leukocytes, increased basophils, decreased lymphocytes, increased platelets, agranulocytosis, sometimes anemia, rarely purpura, decreased platelets, decreased granulocytes, increased eosinophils, increased lymphocytes, and disseminated intravascular coagulation.
8) Digestive system: Gastritis, indigestion, glossitis, thirst, constipation, acute pancreatitis, sometimes nausea, vomiting, abdominal pain, stomach pain, epigastric pain, stomach discomfort, rarely diarrhea, loose stools, and loss of appetite may occur.
9) Circulatory system: Occasionally, chest pain, rarely palpitations, tachycardia, increased blood pressure, arrhythmia, and decreased blood pressure may occur with unknown frequency.
10) Musculoskeletal system: Joint pain and muscle pain may occur.
11) Urinary system: Difficulty urinating and urinary obstruction may occur.
12) Whole body: Edema, fainting, muscle weakness, sometimes general malaise, fever, headache, and in rare cases, pallor and coldness may appear.
13) Others: Pneumonia, laryngitis, pleural effusion, hearing loss, conjunctivitis, visual abnormalities, taste disorders, hair loss, sweating, hyponatremia, decreased serum albumin level, decreased serum potassium level, sometimes decreased protein content in the blood and increased cholesterol and triglyceride levels, difficulty in breathing, chest tightness, and rarely, urinary sugar may occur. Additionally, if the medication is accidentally injected into vascular tissue during administration, inflammation that causes ulcers may occur.
4. General precautions
1) This drug is most effective when administered as early in the disease as possible.
2) During administration of this drug (especially when administering high doses), sufficient fluid intake is necessary to prevent dehydration symptoms and reduce the risk of nephrotoxicity.
5. Interaction
1) It has been reported that the combined use of probenecid and this drug injection extends the average half-life of this drug by 18%, increases the area of the plasma-concentration curve by 40%, and reduces urinary excretion and renal clearance.
2) It has been reported that cimetidine reduces the urinary excretion of this drug and increases the area of the plasma-concentration curve by 27%.
3) It has been reported that the combined use of mycophenolate mofetil and this drug reduces the excretion of mycophenolate mofetil metabolites and increases the area of the plasma-concentration curve of both drugs.
4) When theophylline and this drug are used together, symptoms of theophylline poisoning may appear.
6. Administration to pregnant women
1) As a result of animal testing, teratogenic effects (abnormalities in the head and tail of the fetus) have been reported, so it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) Since the ingredients of this medicine are passed into breast milk, breast-feeding should be discontinued during treatment.
7. Administration to children
For infants, toddlers, and children, administer with caution, limiting use to the minimum necessary. In particular, safety for newborns and premature infants has not been established, so it is administered only when the therapeutic benefits are judged to outweigh the risks.
8. Administration to elderly people
This drug is mainly excreted through the kidneys. Elderly people often have reduced renal function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur. Therefore, administer with caution, paying attention to the dosage and administration interval.
9. Treatment in case of overdose
1) In cases where 20 g of this drug was taken at a time, agitation, lethargy, convulsions, and lethargy were reported as adverse reactions during overdose. In case of overdose, this drug may precipitate in the renal tubules, causing an increase in BUN and serum creatinine, and renal failure. In case of excessive intravenous administration, confusion, hallucinations, excitement, epileptic seizures, and coma may occur.
2) In case of overdose, the blood concentration of this drug should be measured while carefully observing the patient's condition. If symptoms of overdose appear, hemodialysis may be considered to lower the blood concentration of this drug.
10. Application precautions
1) Do not administer by rapid intravenous injection (bolus injection), but only by drip intravenous injection. To reduce risk to renal tubules, administer slowly by intravenous infusion over at least 1 hour.
2) During intravenous drip injection, vascular pain at the injection site and sudden weakening of blood vessels (easy to be exposed to extravasation) may occur at times, so administer carefully to prevent the drug from leaking outside the blood vessels.
3) Prepare the injection solution immediately before administration, shake sufficiently before administration, and discard the remaining solution after use. Additionally, when diluted with supplementary solution, cloudiness or crystals may precipitate due to the supplementary solution, so do not administer in such cases. Do not cool the preparation solution, including the diluted solution, because crystals are likely to precipitate when cooled.
4) This drug is alkaline and can easily change composition due to changes in pH, etc., so avoid mixing injections with other drugs if possible.
11. Others
1) In a bone marrow micronucleus test, it was reported that intraperitoneal administration of high doses (more than 180 mg/kg) to mice may cause chromosomal abnormalities.
2) Several recent studies have shown that this drug causes mutations and reduced spermatogenesis when administered in high doses. However, in human studies within the recommended dose range, there was no effect on sperm count.
4. How to save
Sealed container, stored below 25℃
5. Packaging unit
5 vials
6. Expiration date
60 months from date of manufacture
Product Updates
Total 2items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 2 | Aclova Inj. | Dosage and usage | 2026.01.02 | PDF0001_198601101_Usage and dosage (Ecrova injection).pdf |
| 1 | Aclova Inj. | Ecrobaju (Precautions for use) | 2008.01.02 | HWP9. Ecrobaju (Precautions for use) (2008.01.02).hwp |